Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1 4Phase 2/3 2Phase 1/2 2Phase NA 1Phase 4 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Dermatologic 1

Conditions

Melanoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Carboplatin 9Paclitaxel 8Gemcitabine 8Cisplatin 8Cyclophosphamide 7Fluorouracil 6Docetaxel 5Capecitabine 5Granulocyte Colony-Stimulating Factor 4Etoposide 4Vinorelbine 3Stem Cell Transplantation 3Radiotherapy 3Pemetrexed 3Melphalan 3Leucovorin 3Filgrastim 3Erlotinib Hydrochloride 3Bone Marrow Transplantation 3Bevacizumab 3umbralisib 2ublituximab 2pembrolizumab 2peginterferon alfa-2b 2fludarabine 2Whole-Body Irradiation 2Trastuzumab 2Transplantation, Homologous 2Surveys and Questionnaires 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Terminated × peginterferon alfa-2b × Clear all
NCT03547154 2019-08-12

C98026

Merck Sharp & Dohme LLC

Phase 2/3 Terminated
344 enrolled 11 charts
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03552549 2019-07-24

SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)

Merck Sharp & Dohme LLC

Phase 2/3 Terminated
126 enrolled 9 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡